Drug patent expiry dates are often treated like a calendar footnote—something legal teams track, and sales teams only notice when the market starts to shift. But in a world where launch timing, payer behavior, and competitive entry are increasingly dat…

Sell the line before the patent breaks.
In pharma manufacturing, timing isn’t just operational—it’s commercial. The companies that win in pre-LOE (pre–loss of exclusivity) aren’t waiting for the patent cliff to arrive. They’re building demand before …

The Smarter Monopoly? Orphan Drug Exclusivity vs. Standard Patents—Why the Rules Matter More Than Ever
In a world where innovation is measured in years, not headlines, the pharmaceutical patent system is often treated like a technical footnote. But the…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologic loss-of-exclusivity (LOE) doesn’t arrive with a warning label. It arrives like a cliff—sudden, unforgiving, and expensive to miss…

Generic competition is supposed to be the end of the story. In pharma, it’s often just the beginning.
For years, the public narrative has been straightforward: once a drug’s patent expires, generic manufacturers step in, prices fall, and patients benef…

Patients aren’t asking “about patents.” They’re asking one question: “Will I be able to get my medicine?”
If you’ve spent any time around drug pricing, generics, or biosimilars, you’ve probably noticed a disconnect. The industry debates mechanisms—excl…

Evergreening isn’t a rumor in pharma—it’s a playbook. And if you’re still treating it like a surprise, you’re already behind.
The industry has learned to expect “brand extensions”: new formulations, new dosing regimens, new delivery mechanisms, new com…

GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Actually Changes
The generic drug industry has always lived at the intersection of science and speed. But in 2024, “speed” is no longer just about running more experiments …